Please assess the completion status of the following clinical trial:

Trial Title: Ezetimibe Plus (+) Simvastatin Versus Atorvastatin Comparative Study (0653A-092)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of hypercholesterolemia~* LDL-C \>/= 130 mg/dL but \</=250 mg/dL and triglyceride (TG) \</= 350 mg/dL~* National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III guideline~Exclusion Criteria:~* Hypersensitivity to 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase) inhibitors or Ezetimibe

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vytorin (Type: EXPERIMENTAL): Ezetimibe 10 mg/Simvastatin 20 mg
- Atorvastatin (Type: ACTIVE_COMPARATOR): Atorvastatin 10 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).